Literature DB >> 7858859

Effects of bradykinin B2 receptor antagonism on the hypotensive effects of ACE inhibition.

H Bouaziz1, Y Joulin, M Safar, A Benetos.   

Abstract

1. The aim of this study was to determine the participation of endogenous bradykinin (BK) in the antihypertensive effects of the angiotensin converting enzyme inhibitor (ACEI), perindoprilat, in the spontaneously hypertensive rat (SHR) on different salt diets. 2. Conscious SHRs receiving either a low or a high NaCl diet were used in order to evaluate the respective roles of angiotensin II suppression and bradykinin stimulation in the acute hypotensive effects of perindoprilat. Two different B2 receptor antagonists (B 4146 and Hoe 140) were used after bolus administration of 7 mg kg-1 of the ACEI, perindoprilat. In separate animals, Hoe 140 was administered before the injection of perindoprilat. In other experiments, the effects of Hoe 140 on the hypotensive effects of the calcium antagonist, nicardipine, were tested. 3. The different NaCl diets had no effect on baseline blood pressure. Hoe 140 injection before ACE inhibition did not modify blood pressure. Perindoprilat caused more marked hypotension in the low salt-fed rats than in the high salt animals (P < 0.01). Administration of Hoe 140 or B4146 after perindoprilat significantly reduced the antihypertensive effects of perindoprilat in the different groups, but this effect was more pronounced in high salt-fed rats. However, in SHRs receiving Hoe 140 before perindoprilat, the antihypertensive effect of perindoprilat was completely abolished in both high or low salt diet rats. In separate experiments we confirmed that Hoe 140 did not affect the hypotensive efficacy of the calcium antagonist, nicardipine. 4. Our study shows that inhibition of endogenous bradykinin degradation participates in the acute antihypertensive effects of perindoprilat in SHRs. The role of bradykinin is more pronounced following exposure to a high salt diet i.e., when the renin-angiotensin system is suppressed. Blockade of bradykinin B2 receptors by Hoe 140 before administration of perindoprilat completely abolished the hypotensive effect of perindoprilat suggesting an increased role of bradykinin in the onset of hypotensive action of ACE inhibitors. However, the exact mechanism of this interaction remains unclear.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7858859      PMCID: PMC1510422          DOI: 10.1111/j.1476-5381.1994.tb17052.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  22 in total

1.  Changes in peripheral sympathetic outflow of pithed spontaneously hypertensive rats after bradykinin and DesArg-bradykinin infusions: influence of converting-enzyme inhibition.

Authors:  P Dominiak; M Simon; A Blöchl; P Brenner
Journal:  J Cardiovasc Pharmacol       Date:  1992       Impact factor: 3.105

2.  Salt sensitivity and bradykinin activity in rats.

Authors:  A Benetos; H Bouaziz; M Safar
Journal:  Agents Actions Suppl       Date:  1992

3.  Endogenous bradykinin activity in Dahl rats.

Authors:  A Benetos; H Bouaziz; M Safar
Journal:  J Cardiovasc Pharmacol       Date:  1993-01       Impact factor: 3.105

4.  New, long-acting, potent bradykinin antagonists.

Authors:  F Lembeck; T Griesbacher; M Eckhardt; S Henke; G Breipohl; J Knolle
Journal:  Br J Pharmacol       Date:  1991-02       Impact factor: 8.739

5.  Role of angiotensin converting enzyme and other peptidases in in vivo metabolism of kinins.

Authors:  H Ishida; A G Scicli; O A Carretero
Journal:  Hypertension       Date:  1989-09       Impact factor: 10.190

6.  Pharmacological characterization of a new highly potent B2 receptor antagonist (HOE 140: D-Arg-[Hyp3,Thi5,D-Tic7,Qic8]bradykinin).

Authors:  N E Rhaleb; N Rouissi; D Jukic; D Regoli; S Henke; G Breipohl; J Knolle
Journal:  Eur J Pharmacol       Date:  1992-01-14       Impact factor: 4.432

7.  A specific B2-bradykinin receptor antagonist HOE 140 abolishes the antihypertrophic effect of ramipril.

Authors:  W Linz; B A Schölkens
Journal:  Br J Pharmacol       Date:  1992-04       Impact factor: 8.739

8.  Captopril inhibits endothelin-1 secretion from endothelial cells through bradykinin.

Authors:  N Momose; K Fukuo; S Morimoto; T Ogihara
Journal:  Hypertension       Date:  1993-06       Impact factor: 10.190

9.  Involvement of nitric oxide in the regional haemodynamic effects of perindoprilat and captopril in hypovolaemic Brattleboro rats.

Authors:  S M Gardiner; T Bennett
Journal:  Br J Pharmacol       Date:  1992-12       Impact factor: 8.739

10.  Chronic kinin receptor blockade attenuates the antihypertensive effect of ramipril.

Authors:  G Bao; P Gohlke; F Qadri; T Unger
Journal:  Hypertension       Date:  1992-07       Impact factor: 10.190

View more
  4 in total

1.  Role of bradykinin receptors in the renal effects of inhibition of angiotensin converting enzyme and endopeptidases 24.11 and 24.15 in conscious rabbits.

Authors:  F Tomoda; R A Lew; A I Smith; A C Madden; R G Evans
Journal:  Br J Pharmacol       Date:  1996-09       Impact factor: 8.739

2.  Lack of involvement of bradykinin in the vascular sympathoinhibitory effects of angiotensin converting enzyme inhibitors in spontaneously hypertensive rats.

Authors:  B Chauvin; C Richer; J F Giudicelli
Journal:  Br J Pharmacol       Date:  1995-10       Impact factor: 8.739

Review 3.  The Renin-Angiotensin System in the Development of Salt-Sensitive Hypertension in Animal Models and Humans.

Authors:  Beate Rassler
Journal:  Pharmaceuticals (Basel)       Date:  2010-03-29

4.  Increased Reactive Oxygen Species Generation Contributes to the Atherogenic Activity of the B2 Bradykinin Receptor.

Authors:  Alexander Perhal; Stefan Wolf; Yahya F Jamous; Andreas Langer; Joshua Abd Alla; Ursula Quitterer
Journal:  Front Med (Lausanne)       Date:  2019-02-21
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.